Apricus Biosciences Inc (APRI)

0.35
NASDAQ : Health Care
Prev Close 0.35
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.28 / 1.99
Avg Volume 649.90K
Exchange NASDAQ
Shares Outstanding 66.35M
Market Cap 22.56M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital

Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital

$7.0 Million Equity Facility with Existing Long-Term Shareholder

Apricus Biosciences Provides Corporate Update And First Quarter Financial Results

Apricus Biosciences Provides Corporate Update And First Quarter Financial Results

Vitaros® U.S. NDA Re-Submission on Schedule for 3Q 2016

Apricus Biosciences Announces Year-End 2015 Update And 2016 Growth Strategy

Apricus Biosciences Announces Year-End 2015 Update And 2016 Growth Strategy

Top-Line Phase 2b Data for Fispemifene Expected in Q1

Apricus Biosciences And Ferring Pharmaceuticals Sign Exclusive Distribution Agreement To Market Topical Erectile Dysfunction Cream Vitaros(TM) In Latin American Countries

Apricus Biosciences And Ferring Pharmaceuticals Sign Exclusive Distribution Agreement To Market Topical Erectile Dysfunction Cream Vitaros(TM) In Latin American Countries

Apricus Eligible to Receive Up to $18.25 Million in Upfront and Milestone Payments, in Addition to Royalties on Net Sales

Apricus Reports Top-Line Phase 2a Data For RayVa(TM), Its Topical Treatment For Raynaud's Phenomenon

Apricus Reports Top-Line Phase 2a Data For RayVa(TM), Its Topical Treatment For Raynaud's Phenomenon

Apricus Reaffirms Plans to Move RayVa Into Late-Stage Clinical Trials in Patients With Scleroderma Who Also Suffer From Raynaud's Phenomenon